The UK aesthetics market is fragmented, fast-growing, and opaque.
15,000 clinics, most of them privately-held independents, with financial data scattered across Companies House, treatment information behind booking platforms, and almost no consolidated market reporting. AestheticIQ is the single source of truth for investors, CF boutiques, and corporate buyers looking at this space.
Sector analysis for UK aesthetics needs to combine clinic-level detail (who, where, what treatments) with market-structure intelligence (consolidation, white-space, chain dynamics). Most data sources provide one. AestheticIQ provides both.
M&A & buy-and-build
Target screening, buy-and-build mapping, chain consolidation tracking, add-on identification, revenue proxy modelling.
Sector analysis
Addressable market sizing, white-space identification, regional fragmentation, treatment-mix benchmarks, growth-category tracking.
Portfolio monitoring
Peer benchmarking, competitive density tracking, KPI proxies, post-deal performance monitoring, exit preparation intelligence.
The sector data layer CDDs currently pay consultants to assemble.
Commercial Due Diligence on UK aesthetic investments typically means paying a specialist consultancy £150–400k to assemble market intelligence from scratch. AestheticIQ provides the underlying data layer those projects rely on: pre-built, validated, and continuously refreshed.
Delivered as bespoke project reports or continuous portfolio-monitoring dashboards.
Three use cases. Three deal moments.
Pre-deal screening, in-deal diligence, and post-deal monitoring, each answered by the same underlying dataset.
For M&A teams and buy-and-build strategies.
UK aesthetics is the kind of sector made for roll-up strategies: fragmented, fast-growing, with small independents ripe for consolidation. But identifying credible acquisition targets at clinic-group level requires data that sits across Companies House, treatment offerings, geographic coverage, and chain maturity. AestheticIQ assembles it.
For Commercial Due Diligence and market studies.
The UK aesthetics sector is crying out for rigorous market sizing, white-space mapping, and fragmentation analysis. Most existing studies rely on interview-based top-down estimates. AestheticIQ provides a bottom-up dataset built from clinic-level reality: the 15,000 clinics, their treatment offerings, their chain affiliations, their regional density.
For portfolio operations and asset-management teams.
Post-deal, the question shifts from did we buy right? to is it outperforming peers? AestheticIQ provides continuous peer-benchmarking: how your portfolio clinics compare against local competitors on treatment breadth, brand visibility, pricing position, and review performance. Quarterly reporting for IC decks, early warning on underperformance, and data-driven exit prep.
Show us your thesis. We'll show you the data.
Every investor engagement starts with your specific deal or sector question. 20-minute conversation to show what AestheticIQ can surface for your thesis, no generic pitch.